Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benz(de)isoquinolin-1-one
2. 2-qhbiqo
3. Aloxi
4. Palonosetron
5. Palonosetron, (3r)-
6. Palonosetron, (r-(r*,r*))-isomer
7. Palonosetron, (r-(r*,s*))-isomer
8. Palonosetron, (s-(r*,s*))-isomer
9. Rs 25233 197
10. Rs 25233 198
11. Rs 25233-197
12. Rs 25233-198
13. Rs 25233197
14. Rs 25233198
15. Rs 25259
16. Rs 25259 197
17. Rs 25259 198
18. Rs 25259-197
19. Rs 25259-198
20. Rs 25259197
21. Rs 25259198
22. Rs-25233-197
23. Rs-25233-198
24. Rs-25259
25. Rs-25259-197
26. Rs-25259-198
27. Rs25233197
28. Rs25233198
29. Rs25259
30. Rs25259197
31. Rs25259198
1. 135729-62-3
2. Palonosetron Hcl
3. Aloxi
4. Onicit
5. Palonosetron (hydrochloride)
6. Rs-25259-197
7. (s,s)-palonosetron Hydrochloride
8. Palonocetron Hydrochloride
9. Palonosetron (as Hydrochloride)
10. Chebi:85157
11. Rs 25259-197
12. (3as)-2-(3s)-1-azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1h-benz[de]isoquinolin-1-one Monohydrochloride
13. (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one;hydrochloride
14. 1h-benz[de]isoquinolin-1-one, 2-[(3s)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-, Hydrochloride (1:1), (3as)-
15. 23310d4i19
16. Aloxi (tn)
17. Dsstox_cid_26610
18. Dsstox_rid_81765
19. Dsstox_gsid_46610
20. (3as)-2,3,3a,4,5,6-hexahydro-2-((3s)-3-quinuclidinyl)-1h-benz(de)isoquinolin-1-one Monohydrochloride
21. (s)-2-((s)-quinuclidin-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benzo[de]isoquinolin-1-one Hydrochloride
22. (r,s)-palonosetron Hcl
23. (s,r)-palonosetron Hcl
24. Cas-135729-62-3
25. Palonosetron Related Compound C
26. Palonosetron Related Compound D
27. Onicita
28. Paloxi
29. Palonosetron Hydrochloride [usan]
30. Unii-23310d4i19
31. Palonosetron Hydrochloride [usan:jan]
32. Palonosetronhydrochloride
33. Ncgc00166415-01
34. Chembl1720
35. Mls001424202
36. Schembl182478
37. Rs 25259 197
38. Dtxsid8046610
39. (3as)-palonosetron Hydrochloride
40. Palonosetron Hydrochloride- Bio-x
41. Palonosetron Hydrochloride (aloxi)
42. Ex-a4360
43. Hy-a0021
44. Tox21_112421
45. Mfcd00939524
46. Nsc743769
47. S3050
48. Palonosetron Hydrochloride (jan/usp)
49. Akos015895112
50. Akos026751493
51. Tox21_112421_1
52. Ac-1293
53. Ccg-101081
54. Ccg-221268
55. Cs-0621
56. Nc00331
57. Palonosetron Hydrochloride [mi]
58. Palonosetron Hydrochloride [jan]
59. Ncgc00166415-03
60. (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one Hydrochloride
61. As-75066
62. Bp164227
63. Palonosetron Hydrochloride [mart.]
64. Rs 25259
65. Smr000469233
66. Palonosetron Hydrochloride [usp-rs]
67. Palonosetron Hydrochloride [who-dd]
68. Palonosetron Hydrochloride, >=98% (hplc)
69. P-225
70. P2051
71. Palonosetron Hydrochloride [ema Epar]
72. D05343
73. Palonosetron Hydrochloride [orange Book]
74. 729p623
75. Akynzeo Component Palonosetron Hydrochloride
76. Palonosetron Hydrochloride [usp Monograph]
77. 7-amino-3-(hydroxymethyl)-3-cephem-4-carboxylicacid
78. Palonosetron Hydrochloride Component Of Akynzeo
79. Q27158366
80. (s,r)-palonosetron Hydrochloride Contains Up To ~35% (r,r)-isomer
81. 1h-benz[de]isoquinolin-1-one,3,3a,4,5,6-hexahydro-, (3as)- Hydrochloride
82. 1h-benz[de]isoquinolin-1-one,3,3a,4,5,6-hexahydro-, [s-(r*,r*)]-, Hydrochloride
83. Palonosetron Hydrochloride, United States Pharmacopeia (usp) Reference Standard
84. (3as)-2-[(3s)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1h-benz[de]isoquinolin-1-one Hydrochloride
85. (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1h-benzo[de]isoquinolin-1-one--hydrogen Chloride (1/1)
86. (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one;hydrochloride.
87. (3as)-2-[(s)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1h-benz[de]isoquinoline Hydrochloride
88. (3s)-3-[(3as)-1-oxo-3a,4,5,6-tetrahydro-1h-benzo[de]isoquinolin-2(3h)-yl]-1-azabicyclo[2.2.2]octan-1-ium Chloride
89. (5s)-3-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-azatricyclo[7.3.1.0?,(1)(3)]trideca-1(13),9,11-trien-2-one Hydrochloride
90. 1h-benz(de)isoquinolin-1-one, 2-(3s)-1-azabicyclo(2.2.2)oct-3-yl-2,3,3a,4,5,6-hexahydro-, Monohydrochloride, (3as)-
Molecular Weight | 332.9 g/mol |
---|---|
Molecular Formula | C19H25ClN2O |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 1 |
Exact Mass | 332.1655411 g/mol |
Monoisotopic Mass | 332.1655411 g/mol |
Topological Polar Surface Area | 23.6 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 456 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Palonosetron hydrochloride |
Drug Label | ALOXI (palonosetron hydrochloride) is an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3aS)-2-[(S)-1-Azabicyclo [2.2.2]... |
Active Ingredient | Palonosetron hydrochloride |
Dosage Form | Injectable |
Route | injection |
Strength | 0.25mg/0.25ml; 0.25mg/5ml; 0.05mg/ml; 0.075mg/1.5ml |
Market Status | Tentative Approval |
Company | Teva Pharms; Dr Reddys Labs |
2 of 2 | |
---|---|
Drug Name | Palonosetron hydrochloride |
Drug Label | ALOXI (palonosetron hydrochloride) is an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3aS)-2-[(S)-1-Azabicyclo [2.2.2]... |
Active Ingredient | Palonosetron hydrochloride |
Dosage Form | Injectable |
Route | injection |
Strength | 0.25mg/0.25ml; 0.25mg/5ml; 0.05mg/ml; 0.075mg/1.5ml |
Market Status | Tentative Approval |
Company | Teva Pharms; Dr Reddys Labs |
Aloxi is indicated in adults for:
- the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,
- the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Aloxi is indicated in paediatric patients 1 month of age and older for:
- the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Serotonin 5-HT3 Receptor Antagonists
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS. (See all compounds classified as Serotonin 5-HT3 Receptor Antagonists.)
A04AA05
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-08
Pay. Date : 2013-01-16
DMF Number : 24798
Submission : 2011-03-23
Status : Active
Type : II
NDC Package Code : 58175-0543
Start Marketing Date : 2008-02-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23590
Submission : 2010-03-01
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-914
Start Marketing Date : 2010-03-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Century has been an API manufacturer for over 30 years & is the partner of choice for multipurpose custom manufacturing projects.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21123
Submission : 2007-12-11
Status : Active
Type : II
Date of Issue : 2022-07-28
Valid Till : 2025-06-16
Written Confirmation Number : WC-0036
Address of the Firm :
NDC Package Code : 58032-0135
Start Marketing Date : 2017-12-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-12-17
Pay. Date : 2015-09-28
DMF Number : 28088
Submission : 2015-09-29
Status : Active
Type : II
NDC Package Code : 62147-0218
Start Marketing Date : 2014-04-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21749
Submission : 2008-07-01
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-23
Pay. Date : 2012-11-09
DMF Number : 23332
Submission : 2009-12-03
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?